NGM Biopharmaceuticals, Inc. (NGM)
| Market Cap | 1.06B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -125.24M |
| Shares Out | 79.26M |
| EPS (ttm) | -1.56 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 290,540 |
| Open | 13.50 |
| Previous Close | 13.58 |
| Day's Range | 12.98 - 13.58 |
| 52-Week Range | 10.49 - 29.58 |
| Beta | 1.77 |
| Analysts | Buy |
| Price Target | 35.70 (+167.4%) |
| Earnings Date | May 9, 2022 |
About NGM
NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); and MK-3655, an agonistic antibody that activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase IIb clinical trials for ...
Financial Performance
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for NGM stock is "Buy." The 12-month stock price forecast is 35.7, which is an increase of 167.42% from the latest price.
News
NGM Biopharmaceuticals (NGM) Reports Q1 Loss, Lags Revenue Estimates
NGM Biopharmaceuticals (NGM) delivered earnings and revenue surprises of 0% and 6.26%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
NGM Bio Provides Business Highlights and Reports First Quarter 2022 Financial Results
SOUTH SAN FRANCISCO, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeut...
5 Graham's Lost Formula Biotech Stocks to Consider for May
After a brutal month in April, U.S. market indexes were lower on Tuesday as investors await the Federal Open Market Committee's decision on interest rates.
NGM Bio to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., April 20, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therape...
NGM Bio to Present Late-Breaking Preclinical Research at 2022 AACR Annual Meeting Supporting Development of its Myelo...
SOUTH SAN FRANCISCO, Calif., April 08, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therape...
NGM Bio Announces Oral and Late-Breaking Poster Presentations Supporting Its Myeloid Reprogramming Portfolio at Upcom...
SOUTH SAN FRANCISCO, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therape...
NGM Biopharmaceuticals (NGM) Reports Q4 Loss, Tops Revenue Estimates
NGM Biopharmaceuticals (NGM) delivered earnings and revenue surprises of 5.41% and 4.10%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
NGM Bio Provides Business Highlights and Reports Fourth Quarter and Full Year 2021 Financial Results
Advanced programs across NGM Bio's pipeline in retinal diseases, oncology and liver and metabolic diseases during the fourth quarter and beginning of 2022
NGM Bio to Participate in the Cowen 42nd Annual Health Care Conference
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeu...
NGM Bio (NGM) Up on Fast Track Tag For Ophthalmology Drug
The FDA bestows a Fast Track designation to NGM Bio's (NGM) product candidate, NGM621, for treating patients with geographic atrophy secondary to age-related macular degeneration. Stock up.
NGM Bio's NGM621 Receives Fast Track Designation from the FDA for the Treatment of Patients with Geographic Atrophy S...
SOUTH SAN FRANCISCO, Calif., Feb. 07, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeu...
NGM Bio Outlines 2022 Strategic Priorities Across Its Portfolio of Clinical-Stage Oncology, Retinal and Liver and Met...
SOUTH SAN FRANCISCO, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeu...
NGM Bio Announces Clinical Trial Collaboration with Merck Related to Ongoing Phase 1/2 Trial of NGM707, an ILT2/ILT4 ...
SOUTH SAN FRANCISCO, Calif., Dec. 06, 2021 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics...
NGM Biopharmaceuticals (NGM) Reports Q3 Loss, Lags Revenue Estimates
NGM Biopharmaceuticals (NGM) delivered earnings and revenue surprises of 2.63% and -1.74%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
NGM Biopharmaceuticals (NGM) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
NGM Biopharmaceuticals (NGM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is Good News Enough for You to Buy NGM on the Dip?
A drop in the overall market provides an opportunity for investors to pounce.
NGM Bio Presents Preliminary Data From NGM120 Solid Tumor Trial
NGM Biopharmaceuticals Inc (NASDAQ: NGM) announced preliminary findings from its ongoing Phase 1a/1b dose-escalation study of NGM120 in solid tumors. Related Link: Raymond James Upgraded This Biopharm...
Raymond James Upgraded This Biopharma Stock And Sees 44% Upside
Raymond James has upgraded NGM Biopharmaceuticals Inc (NASDAQ:NGM) to Strong Buy from Outperform with a price target of $39, up from $27, almost 44% upside. Analyst Steven Seedhouse notes the validation...
NGM Bio Discloses Fourth Oncology Development Candidate, NGM831, an ILT3 Antagonist Antibody, Coinciding with Publica...
SOUTH SAN FRANCISCO, Calif., Aug. 23, 2021 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics...
NGM Biopharmaceuticals (NGM) Reports Q2 Loss, Lags Revenue Estimates
NGM Biopharmaceuticals (NGM) delivered earnings and revenue surprises of -23.08% and -24.02%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
NGM Biopharmaceuticals (NGM) Expected to Beat Earnings Estimates: Should You Buy?
NGM Biopharmaceuticals (NGM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What Makes NGM Biopharmaceuticals (NGM) a New Buy Stock
NGM Biopharmaceuticals (NGM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
NGM Biopharma, Merck Amend Development Pact To Focus On Retinal, Cardiovascular & Metabolic Targets
NGM Biopharmaceuticals Inc (NASDAQ: NGM) has amended and restated an agreement with Merck & Co Inc (NYSE: MRK) to extend their ongoing collaboration through March 2024 with a narrower scope. The collab...
NGM Amends Collaboration with Merck to Focus Primarily on Advancing Novel Medicines for Retinal and Cardiovascular an...
SOUTH SAN FRANCISCO, Calif., July 01, 2021 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) today announced that the company has entered into an amended and restated agreement with Merck, known as...
NGM Biopharmaceuticals (NGM) Stock Jumps 7%: Will It Continue to Soar?
NGM Biopharmaceuticals (NGM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more...